MedTrace Logo

Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

NCT00624780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 615

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Pregabalin

Pregabalin 150-300 mg given twice a day

DRUG

Lorazepam

Lorazepam 3-4 mg given twice a day

DRUG

Pregabalin

Pregabalin 450-600 mg given twice a day

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • Argentina
  • Austria
  • Costa Rica
  • Croatia
  • Czechia
  • Finland
  • Greece
  • India
  • Indonesia
  • Lithuania
  • Mexico
  • Russia
  • Serbia
  • Slovenia
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00624780 on ClinicalTrials.gov